Search

Your search keyword '"Małyszko, Jolanta"' showing total 812 results
Start Over Author "Małyszko, Jolanta"
812 results on '"Małyszko, Jolanta"'

6. Efficacy of erythropoietin as a neuroprotective agent in CKD-associated cognitive dysfunction: A literature systematic review

Author

Barbieri, Michelangela, Chiodini, Paolo, Di Gennaro, Piergiacomo, Hafez, Gaye, Liabeuf, Sophie, Malyszko, Jolanta, Mani, Laila-Yasmin, Mattace-Raso, Francesco, Pepin, Marion, Perico, Norberto, Simeoni, Mariadelina, Zoccali, Carmine, Tortorella, Giovanni, Capuano, Annalisa, Remuzzi, Giuseppe, Capasso, Giovambattista, and Paolisso, Giuseppe

Published
2024
Full Text
View/download PDF

15. Challenges in the management of the kidney allograft: from decline to failure: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Ahn, Curie, Alberú, Josefina, Baliker, Mary, Bamgboye, Ebun L., Barber, Thelma, Bensouda, Melissa, Chadban, Steve J., Dadhania, Darshana M., Dębska-Ślizień, Alicja, Devresse, Arnaud, Ditzen, Beate, Fowler, Kevin, Gill, John S., Jha, Vivekanand, Khairallah, Pascale, Knoll, Greg A., Korst, Uwe, Lee, Austin, Legendre, Christophe, Lentine, Krista L., Lerma, Edgar V., Lorenz, Elizabeth C., Matas, Arthur J., Mohan, Sumit, Nazarewski, Sławomir, Noronha, Irene L., Obrador, Gregorio T., Parekh, Rulan S., Pavlakis, Martha, Pascual, Julio, Pilmore, Helen L., Rosenkranz, Alexander R., Rozen-Zvi, Benaya, Roy-Chaudhury, Prabir, Tanabe, Kazunari, Wanner, Christoph, Wasse, Haimanot, Yang, Chul-Woo, Josephson, Michelle A., Becker, Yolanda, Budde, Klemens, Kasiske, Bertram L., Kiberd, Bryce A., Loupy, Alexandre, Małyszko, Jolanta, Mannon, Roslyn B., Tönshoff, Burkhard, Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C., and Zeier, Martin

Published
2023
Full Text
View/download PDF

16. Trends and perspectives for improving quality of chronic kidney disease care: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Al-Aly, Ziyad, Ashuntantang, Gloria E., Boor, Peter, Calice da Silva, Viviane, Coleman, Jill, Coresh, Josef, Delanaye, Pierre, Ebert, Natalie, Enghard, Philipp, Feldman, Harold I., Fisher, Lori, Flythe, Jennifer E., Fukui, Akira, Grams, Morgan E., Ix, Joseph H., Jardine, Meg J., Jha, Vivek, Ju, Wenjun, Jurish, Robert, Kalyesubula, Robert, Kashihara, Naoki, Levey, Andrew S., Levin, Adeera, Luyckx, Valerie, Małyszko, Jolanta, Manski-Nankervis, Jo-Anne, Navaneethan, Sankar D., Obrador, Greg, Ortiz, Alberto, Ortiz, John, Cardoso Dos Santos, Bento Fortunato, Sarnak, Mark J., Schaeffner, Elke, Selby, Nick M., Simpson, David M., Solá, Laura, St. Peter, Wendy L., Stevens, Paul E., Tangri, Navdeep, Tannor, Elliot Koranteng, Tchokhonelidze, Irma, Wilck, Nicola, Wong, Michelle M.Y., Eckardt, Kai-Uwe, Delgado, Cynthia, Heerspink, Hiddo J.L., Pecoits-Filho, Roberto, Ricardo, Ana C., Stengel, Bénédicte, Tonelli, Marcello, Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C., and Kramer, Holly

Published
2023
Full Text
View/download PDF

17. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Afsar, Baris, Akizawa, Tadao, Anker, Stefan D., Arici, Mustafa, Babitt, Jodie L., Barratt, Jonathan, Berns, Jeffrey S., Besarab, Anatole, Bhandari, Sunil, Brown, Christopher, Cases, Aleix, Chertow, Glenn M., Delgado, Cynthia, Drüeke, Tillman B., Fishbane, Steven, Gómez, Rafael, Grams, Morgan E., Hamano, Takayuki, Hao, Chuan-Ming, Hsu, Raymond K., Iseki, Kunitoshi, Jordans, Isabelle, Lerma, Edgar V., Locatelli, Francesco, Macdougall, Iain C., Małyszko, Jolanta, Maxwell, Patrick, McMahon, Lawrence P., Obrador, Gregorio T., Ostermann, Marlies, Pecoits-Filho, Roberto, Perwad, Farzana, Roger, Simon D., Singh, Ajay K., Solá, Laura, Spinowitz, Bruce S., Sugahara, Mai, Takahashi, Toshiyuki, Tanaka, Mototsugu, Tanaka, Tetsuhiro, Tarng, Der-Cherng, Tonelli, Marcello, Tsukamoto, Yusuke, Walther, Carl P., Yee-Moon Wang, Angela, Kong, Hong, Warady, Bradley A., Webster, Angela C., Weir, Matthew R., Wish, Jay B., Wong, Muh Geot, Ku, Elaine, Del Vecchio, Lucia, Eckardt, Kai-Uwe, Haase, Volker H., Johansen, Kirsten L., Nangaku, Masaomi, Tangri, Navdeep, Waikar, Sushrut S., Więcek, Andrzej, Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C., and Wheeler, David C.

Published
2023
Full Text
View/download PDF

18. Managing the symptom burden associated with maintenance dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Bagasha, Peace, Bargman, Joanne M., Bavanandan, Sunita, Beckwith, Hannah, Bennett, Paul N., Bohm, Clara, Brennan, Frank, Burton, James O., Cavanaugh, Kerri L., Chilcot, Joseph, Choi, Peter, Cukor, Daniel, Dember, Laura M., Dong, Jie, Edwards, Dawn, Erickson, Kevin F., Figueiredo, Ana, Finkelstein, Fredric O., Fukagawa, Masafumi, Germain, Michael, Guillano, Franklin B., Hurst, Helen, Iseki, Kunitoshi, Jardine, Meg J., Jauré, Allison, Jha, Vivekanand, Jhamb, Manisha, Kanjanabuch, Talerngsak, Lerma, Edgar, Kam-Tao Li, Philip, Liew, Adrian, Małyszko, Jolanta, Proenca de Moraes, Thyago, Moranne, Olivier, Nam Ng, Marques Shek, Ostermann, Marlies, Perl, Jeffrey, Pigford, Jayne, Pommer, Wolfgang, Richardson, Michelle M., Rivara, Matthew B., Roberts, Glenda V., Sarafidis, Pantelis, Shroff, Rukshana, Slon Roblero, Maria Fernanda, Smyth, Brendan, Søndergaard, Henning, Van Der Veer, Sabine N., Vassalotti, Joseph A., Vervloet, Marc, Vincent, Lloyd, Walker, Rachael, Warren, Madeleine, Wasylynuk, Betty Ann, West, Melissa, Wilkie, Caroline, Mehrotra, Rajnish, Davison, Sara N., Farrington, Ken, Flythe, Jennifer E., Foo, Marjorie, Madero, Magdalena, Morton, Rachael L., Tsukamoto, Yusuke, Unruh, Mark L., Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C., and Brown, Edwina A.

Published
2023
Full Text
View/download PDF

19. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference

Author

Ostermann, Marlies, Bellomo, Rinaldo, Burdmann, Emmanuel A, Doi, Kent, Endre, Zoltan H, Goldstein, Stuart L, Kane-Gill, Sandra L, Liu, Kathleen D, Prowle, John R, Shaw, Andrew D, Srisawat, Nattachai, Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C, Kellum, John A, Participants, Conference, Bagshaw, Sean M, Barreto, Erin F, Bihorac, Azra, Bobek, Ilona, Bouchard, Josée, Cerdá, Jorge, Chakravarthi, Rajasekara, De Rosa, Silvia, Engelman, Daniel T, Forni, Lui G, Hemmilä, Ulla K, Herzog, Charles A, Hoste, Eric A, Huen, Sarah C, Iseki, Kunitoshi, Joannidis, Michael, Kashani, Kianoush B, Koyner, Jay L, Kribben, Andreas, Lameire, Norbert, Levey, Andrew S, Macedo, Etienne, Małyszko, Jolanta, Meersch, Melanie, Mehta, Ravindra L, Mewburn, Irene, Mironova, Olga, Murray, Patrick T, Nadim, Mitra K, Pan, Jenny S, Pannu, Neesh, Peng, Zhiyong, Philips, Barbara, Ponce, Daniela, Ray, Patricio E, Ricci, Zaccaria, Rimmelé, Thomas, Ronco, Claudio, Siew, Edward D, Stevens, Paul E, Tolwani, Ashita J, Tonelli, Marcello, Vaara, Suvi T, van Dam, Marjel, Vijayan, Anitha, Wise, Michael, Wu, Vin-Cent, and Zarbock, Alexander

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Kidney Disease, 7.3 Management and decision making, Management of diseases and conditions, Renal and urogenital, Acute Kidney Injury, Humans, acute kidney disease, acute kidney injury, fluid management, nephrotoxicity, renal replacement therapy, risk stratification, Conference Participants, Urology & Nephrology, Clinical sciences
Abstract

In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline on the classification and management of acute kidney injury (AKI). The guideline was derived from evidence available through February 2011. Since then, new evidence has emerged that has important implications for clinical practice in diagnosing and managing AKI. In April of 2019, KDIGO held a controversies conference entitled Acute Kidney Injury with the following goals: determine best practices and areas of uncertainty in treating AKI; review key relevant literature published since the 2012 KDIGO AKI guideline; address ongoing controversial issues; identify new topics or issues to be revisited for the next iteration of the KDIGO AKI guideline; and outline research needed to improve AKI management. Here, we present the findings of this conference and describe key areas that future guidelines may address.

Published
2020

20. Scope and Consistency of Cancer Outcomes Reported in Randomized Trials in Kidney Transplant Recipients

Author

Au, Eric H., Wong, Germaine, Tong, Allison, Teixeira-Pinto, Armando, van Zwieten, Anita, Dobrijevic, Ellen, Ahn, Curie, Blosser, Christopher D., Davidson, Bianca, Francis, Anna, Jhaveri, Kenar D., Malyszko, Jolanta, Mena-Gutierrez, Alejandra, Newell, Kenneth A., Palmer, Sarah, Scholes-Robertson, Nicole, Silva Junior, Helio Tedesco, and Craig, Jonathan C.

Published
2023
Full Text
View/download PDF

31. The Clock Drawing Task reveals executive dysfunction in the dialysis population – an underrecognized and underestimated problem.

Author

Olejnik, Piotr, Golenia, Aleksandra, Maciejewska, Oliwia, Wojtaszek, Ewa, Żebrowski, Paweł, and Małyszko, Jolanta

Subjects
DIALYSIS (Chemistry), RENAL replacement therapy, CHRONIC kidney failure, HEMODIALYSIS, CARDIOVASCULAR diseases risk factors
Abstract

The study aimed to assess the prevalence of executive function impairment among patients with chronic kidney disease (CKD) undergoing dialysis, with no subjective cognitive problems and with normal global cognition on the Mini-Mental State Examination (MMSE). We also investigated the relationship between cardiovascular risk factors and cognitive test results. Patients with CKD, including those undergoing renal replacement therapy, are at a higher risk of developing cognitive impairment (CI) than the general population. Recent research has shown CI to be a growing problem among CKD patients worldwide. Yet, it remains underdiagnosed, even though it may significantly influence the lives of patients. In this cross-sectional, prospective study, 58 dialysis patients with no cognitive decline on the MMSE screening were assessed for executive function impairment using the Executive Clock-Drawing Task (CLOX). Moreover, past medical history, demographic data, and laboratory test results were collected. The mean patient age was 59.47 ± 14.98 years, and the mean duration of dialysis was 45.93 ± 48.49 months. The prevalence of executive function impairment amounted to 8.6%. Moreover, remarkably similar pattern of clock drawing was observed, with numbers written outside the clock face in the CLOX1 test. Executive dysfunctions in dialysis patients may manifest itself before the onset of global cognitive impairment. There appear to be a deficit in the spatial domain as well. Better education may play a protective role. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Proenkephalin A 119–159 in Perioperative and Intensive Care—A Promising Biomarker or Merely Another Option?

Author

Walczak-Wieteska, Paulina, Zuzda, Konrad, Małyszko, Jolanta, and Andruszkiewicz, Paweł

Subjects
ACUTE kidney failure, BRAIN injuries, INTENSIVE care units, GLOMERULAR filtration rate, ISCHEMIC stroke
Abstract

Acute kidney injury (AKI) is a severe and prevalent syndrome, primarily observed in intensive care units (ICUs) and perioperative settings. The discovery of a new biomarker for kidney function and injury, capable of overcoming the limitations of traditional markers, has the potential to improve the diagnosis and management of AKI. Proenkephalin A 119–159 (PENK) has emerged as a novel biomarker for AKI and has been validated in various clinical settings. It has demonstrated a faster response to AKI compared to creatinine and has been shown to predict successful weaning from renal replacement therapy in the ICU. PENK has also shown promise as an AKI biomarker in perioperative patients. Additionally, PENK has been proven to be effective in estimating mortality and morbidity in patients undergoing cardiac surgery, and those with traumatic brain injury or ischemic stroke. Incorporating PENK into a novel estimation of the glomerular filtration rate, referred to as the PENK-Crea equation, has yielded promising results. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Sedentary Lifestyle Is a Modifiable Risk Factor for Cognitive Impairment in Patients on Dialysis and after Kidney Transplantation.

Author

Golenia, Aleksandra, Olejnik, Piotr, Maciejewska, Oliwia, Wojtaszek, Ewa, Żebrowski, Paweł, and Małyszko, Jolanta

Subjects
CHRONIC kidney failure, DISEASE risk factors, RENAL replacement therapy, HEMODIALYSIS patients, PERITONEAL dialysis, REMINISCENCE therapy
Abstract

Background: Chronic kidney disease (CKD) is a risk factor for cognitive impairment (CI), and this risk is the highest in patients with end-stage kidney disease (ESKD). As a multifactorial disease, CI may be influenced by several potentially modifiable lifestyle and behavioral factors that may reduce or increase the risk of dementia. The aim of this study was to evaluate the associations between the known modifiable risk factors for dementia and the risk of CI in patients with ESKD treated with renal replacement therapy. The Charlson Comorbidity Index and the risk of CI in patients with ESKD were also assessed. Methods: In this cross-sectional study, 225 consecutive patients with ESKD treated with different modalities of renal replacement therapy were assessed for cognitive decline using the Addenbrooke's Cognitive Examination (ACE III) test. Information was also collected on modifiable risk factors for dementia, medical history and demographics. Results: This study included 117 patients after kidney transplantation (KT) and 108 patients with ESKD undergoing peritoneal dialysis and hemodialysis. The prevalence of modifiable risk factors for dementia differed between the groups; KT patients were more likely to be physically active, residing in cities with populations of less than 500,000 inhabitants, and were less likely to suffer from depression. Furthermore, the KT group had a lower Charlson Comorbidity Index score, indicating less severe comorbidities, and a lower risk of CI (3.6 ± 1.67 vs. 5.43 ± 2.37; p = 0.001). In both the KT and dialysis groups, patients with CI were more likely to have a sedentary lifestyle (45% vs. 9%, p = 0.001 and 88% vs. 48%, p = 0.001, respectively), whereas lower educational attainment and depression had a significant negative impact on ACE III test results, but only in KT patients. Finally, cognitive function in dialysis patients was negatively affected by social isolation and living in urban areas. Conclusions: Modifiable risk factors for dementia, particularly a sedentary lifestyle, are associated with a higher risk of CI in patients treated with different renal replacement therapy modalities. As CI is an irreversible condition, it is important to identify lifestyle-related factors that may lead to dementia in order to improve or maintain cognitive function in patients with ESKD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association.

Author

Stoumpos, Sokratis, Crowe, Kirsty, Sarafidis, Pantelis, Barratt, Jonathan, Bolignano, Davide, Vecchio, Lucia Del, Małyszko, Jolanta, Więcek, Andrzej, Ortiz, Alberto, and Cozzolino, Mario

Subjects
IRON in the body, CLINICAL trials, HYPOXIA-inducible factors, CHRONIC kidney failure, ANEMIA treatment
Abstract

Anaemia is a common complication of chronic kidney disease (CKD) and is associated with poor long-term outcomes and quality of life. The use of supplemental iron, erythropoiesis-stimulating agents (ESAs) and blood transfusions has been the mainstay for treatment of anaemia in CKD for more than 3 decades. Despite available treatments, CKD patients with anaemia are undertreated and moderate–severe anaemia remains prevalent in the CKD population. Anaemia has consistently been associated with greater mortality, hospitalization, cardiovascular events and CKD progression in CKD patients, and the risk increases with anaemia severity. Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors have a novel mechanism of action by mimicking the body's response to hypoxia and have emerged as an alternative to ESAs for treatment of anaemia in CKD. Their efficacy in correcting and maintaining haemoglobin has been demonstrated in >30 phase 3 clinical trials. Additionally, HIF activation results in various pleiotropic effects beyond erythropoiesis, with cholesterol reduction and improved iron homeostasis and potential anti-inflammatory effects. The long-term safety of these agents, particularly with respect to cardiovascular and thromboembolic events, and their possible effect on tumour growth needs to be fully elucidated. This article presents in detail the effects of HIF-PH inhibitors, describes their mechanisms of action and pharmacologic properties and discusses their place in the treatment of anaemia in CKD according to the available evidence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Nephrology in Poland

Author

Lichodziejewska-Niemierko, Monika, Czerwiński, Jarosław, Dębska-Ślizień, Alicja, Gellert, Ryszard, Grenda, Ryszard, Małyszko, Jolanta, Naumnik, Beata, Nowicki, Michał, Ostrowski, Janusz, Więcek, Andrzej, Moura-Neto, José A., editor, Divino-Filho, José Carolino, editor, and Ronco, Claudio, editor

Published
2021
Full Text
View/download PDF

40. Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference

Author

Caskey, Fergus J., Farmer, Chris K.T., Ferreiro Fuentes, Alejandro, Fukagawa, Masafumi, Goldstein, Stuart L., Igiraneza, Grace, Kribben, Andreas, Lerma, Edgar V., Levey, Andrew S., Liu, Kathleen D., Małyszko, Jolanta, Ostermann, Marlies, Pannu, Neesh, Ronco, Claudio, Sawhney, Simon, Shaw, Andrew D., Srisawat, Nattachai, Lameire, Norbert H., Levin, Adeera, Kellum, John A., Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C., and Stevens, Paul E.

Published
2021
Full Text
View/download PDF

41. Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Ademi, Zanfina, Chang, Tara I., Clark, Tim, Cooper, Chris, Criqui, Michael, de Bhailis, Áine, De Carlo, Marco, Döhner, Wolfram, Engelman, Daniel T., Fowkes, Gerry, Green, Darren, Hamdan, Allen, Heiss, Christian, Huppert, Peter, Kadian-Dodov, Daniella, Lip, Gregory Y.H., Małyszko, Jolanta, Mark, Patrick B., Miglinas, Marius, Murray, Patrick, Reid, Chris, Rochon, Paul, Ruturi, Josiah, Saratzis, Athanasios, Sarnak, Mark J., Shanahan, Cathy M., Solá, Laura, Teichgräber, Ulf, Textor, Stephen C., Toyoda, Kazunori, Yee-Moon Wang, Angela, Wong, Chris X., Johansen, Kirsten L., Garimella, Pranav S., Hicks, Caitlin W., Kalra, Philip A., Kelly, Dearbhla M., Martens, Sven, Matsushita, Kunihiro, Sarafidis, Pantelis, Sood, Manish M., Herzog, Charles A., Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C., and Reinecke, Holger

Published
2021
Full Text
View/download PDF

42. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference

Author

Abu-Alfa, Ali K., Afsar, Baris, Pai, Amy Barton, Besarab, Anatole, Moore, Geraldine Biddle, Casadevall, Nicole, Cases, Aleix, de Francisco, Angel, Eckardt, Kai-Uwe, Fishbane, Steven, Fried, Linda F., Ganz, Tomas, Ginzburg, Yelena Z., Gómez, Rafael, Goodnough, Lawrence T., Hamano, Takayuki, Hanudel, Mark R., Hao, Chuan-Ming, Iseki, Kunitoshi, Ix, Joachim H., Johansen, Kirsten L., Ketteler, Markus, Kovesdy, Csaba P., Leaf, David E., Macdougall, Iain C., Massy, Ziad A., McMahon, Lawrence P., Minutolo, Roberto, Nakanishi, Takeshi, Nemeth, Elizabeta, Obrador, Gregorio T., Parfrey, Patrick S., Park, Hyeong-Cheon, Pecoits-Filho, Roberto, Robinson, Bruce M., Roger, Simon D., Shah, Yatrik M., Spinowitz, Bruce S., Tanaka, Tetsuhiro, Tsukamoto, Yusuke, Tungsanga, Kriang, Walther, Carl P., Yee-Moon Wang, Angela, Wolf, Myles, Babitt, Jodie L., Eisenga, Michele F., Haase, Volker H., Kshirsagar, Abhijit V., Levin, Adeera, Locatelli, Francesco, Małyszko, Jolanta, Swinkels, Dorine W., Tarng, Der-Cherng, Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C., and Drüeke, Tilman B.

Published
2021
Full Text
View/download PDF

44. Chemotherapy in patients with testicular germ-cell tumors and end-stage renal disease requiring hemodialysis: two case reports.

Author

Tyszka, Martyna, Róg, Letycja, Małyszko, Jolanta, and Stec, Rafał

Subjects
CHRONIC kidney failure, GERM cell tumors, ANTINEOPLASTIC agents, SEMINOMA, HEMODIALYSIS patients, KIDNEY tumors, TESTICULAR cancer
Abstract

The number of patients with end-stage renal disease requiring hemodialysis and diagnosed with various types of cancer is constantly growing, but guidelines on systemic treatment in this particular clinical scenario are lacking. Testicular cancer is a highly curable malignancy, but data on post-orchidectomy systemic treatment based on cisplatin in patients requiring hemodialysis are scarce. We present two cases of patients with testicular germ cell tumors (one intermediate-risk seminoma and one low-risk non-seminoma) treated with chemotherapy while on hemodialysis in our center. Furthermore, we discuss the appropriate doses of cytotoxic drugs and the timing of hemodialysis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation

Author

Abu-Alfa, Ali K., Amer, Hatem, Beutel, Gernot, Chapman, Jeremy, Chen, Xiaohong, Chudek, Jerzy, Cosmai, Laura, Danesi, Romano, De Stefano, Filippo, Iseki, Kunitoshi, Jaimes, Edgar A., Jhaveri, Kenar D., Jurczyszyn, Artur, Kazancioğlu, Rümeyza, Kitchlu, Abhijat, Kollmannsberger, Christian, Lahoti, Amit, Li, Yang, Macía, Manuel, Matsubara, Takeshi, Mitropoulos, Dionysios, Noiri, Eisei, Perazella, Mark A., Ronco, Pierre, Rosner, Mitchell H., Soler Romeo, Maria Jose, Sprangers, Ben, Stadler, Walter M., Stevens, Paul E., Tesař, Vladimír, Torres da Costa e Silva, Verônica, Vesole, David H., Vijayan, Anitha, Viklický, Ondřej, Workeneh, Biruh T., Yanagita, Motoko, Zakharova, Elena, Małyszko, Jolanta, Bamias, Aristotelis, Danesh, Farhad R., Dębska-Ślizień, Alicja, Gallieni, Maurizio, Gertz, Morie A., Kielstein, Jan T., Tesarova, Petra, Wong, Germaine, Cheung, Michael, Wheeler, David C., Winkelmayer, Wolfgang C., and Porta, Camillo

Published
2020
Full Text
View/download PDF

49. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer

Author

Abu-Alfa, Ali K., Amer, Hatem, Beutel, Gernot, Chapman, Jeremy, Chen, Xiaohong, Chudek, Jerzy, Cosmai, Laura, Danesi, Romano, De Stefano, Filippo, Iseki, Kunitoshi, Jaimes, Edgar A., Jhaveri, Kenar D., Jurczyszyn, Artur, Kazancioğlu, Rümeyza, Kitchlu, Abhijat, Kollmannsberger, Christian, Lahoti, Amit, Li, Yang, Macía, Manuel, Matsubara, Takeshi, Mitropoulos, Dionysios, Noiri, Eisei, Perazella, Mark A., Ronco, Pierre, Rosner, Mitchell H., Soler Romeo, Maria Jose, Sprangers, Ben, Stadler, Walter M., Stevens, Paul E., ladimír Tesař, Torres da Costa e Silva, Verônica, Vesole, David H., Vijayan, Anitha, Viklický, Ondřej, Workeneh, Biruh T., Yanagita, Motoko, Zakharova, Elena, Porta, Camillo, Bamias, Aristotelis, Danesh, Farhad R., Dębska-Ślizień, Alicja, Gallieni, Maurizio, Gertz, Morie A., Kielstein, Jan T., Tesarova, Petra, Wong, Germaine, Cheung, Michael, Wheeler, David C., Winkelmayer, Wolfgang C., and Małyszko, Jolanta

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results